Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Clinical trial NCT06170788 · RECRUITING
Trial details
- NCT number
- NCT06170788
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-15
- Primary completion
- 2028-01-25
- Enrollment
- 614
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.